SPRY · NASDAQ
ARS Pharmaceuticals (SPRY) Stock Price & Fundamentals
ARS Pharmaceuticals (SPRY) closed at $243.87 on Oct 9, 2026, up 0.39% from the previous close of $242.93.
Share price, past year
1Y −13.85%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $243.87 |
| Sep 30, 2026 | $239.26 |
| Aug 31, 2026 | $249.56 |
| Jul 31, 2026 | $253.26 |
| Jun 30, 2026 | $260.53 |
| May 29, 2026 | $259.64 |
| Apr 30, 2026 | $256.63 |
| Mar 31, 2026 | $275.38 |
| Feb 27, 2026 | $271.70 |
| Jan 30, 2026 | $273.85 |
| Dec 31, 2025 | $271.60 |
| Nov 28, 2025 | $280.34 |
| Oct 31, 2025 | $287.22 |
Key statistics
- Market cap
- $24.25B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $116.93M
- Net income (TTM)
- −$215.43M
- Shares outstanding
- 99.4M
- Dividend yield
- —
- 52-week range
- $237.67 – $306.36
ARS Pharmaceuticals's market cap is $24.25B, based on a share price of $243.87 and 99.4M shares outstanding as of Jun 30, 2026.
Financials
ARS Pharmaceuticals reported revenue of $84.28M for fiscal 2025, down 5.46% from fiscal 2024.
ARS Pharmaceuticals reported a net loss of $171.30M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $84.28M | −5.5% | −$171.30M | −203.3% | −$1.74 | −$171.21M |
| FY2024ended Dec 31, 2024 | $89.15M | +297,063.3% | $8.00M | 9.0% | $0.08 | $12.99M |
| FY2023ended Dec 31, 2023 | $30.00K | −97.7% | −$54.37M | −181,216.7% | −$0.57 | −$59.44M |
| FY2022ended Dec 31, 2022 | $1.32M | −76.1% | −$34.68M | −2,635.4% | −$0.87 | −$40.28M |
| FY2021ended Dec 31, 2021 | $5.51M | — | −$20.24M | −367.7% | −$0.70 | −$17.62M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $33.66M | −$62.34M | −$0.63 |
| Q1 FY2026ended Mar 31, 2026 | $22.68M | −$60.62M | −$0.61 |
| Q4 FY2025ended Dec 31, 2025 | $28.09M | −$41.32M | — |
| Q3 FY2025ended Sep 30, 2025 | $32.50M | −$51.15M | −$0.52 |
| Q2 FY2025ended Jun 30, 2025 | $15.72M | −$44.88M | −$0.46 |
| Q1 FY2025ended Mar 31, 2025 | $7.97M | −$33.94M | −$0.35 |
| Q4 FY2024ended Dec 31, 2024 | $86.58M | $49.93M | — |
| Q3 FY2024ended Sep 30, 2024 | $2.07M | −$19.13M | −$0.20 |
Company profile
- Name
- ARS Pharmaceuticals, Inc.
- Ticker
- SPRY
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 11682 El Camino Real, Suite 300, San Diego, CA 92130
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001671858
Recent SEC filings
- Aug 13, 2026
- Aug 13, 2026
- Jul 17, 2026
- Jul 7, 2026
- Jun 25, 2026
- May 15, 2026
- May 15, 2026
- May 13, 2026
Frequently asked questions
What is ARS Pharmaceuticals's stock price?
ARS Pharmaceuticals (SPRY) closed at $243.87 on Oct 9, 2026, up 0.39% from the previous close of $242.93.
What is ARS Pharmaceuticals's market cap?
ARS Pharmaceuticals's market cap is $24.25B, based on a share price of $243.87 and 99.4M shares outstanding as of Jun 30, 2026.
How much revenue does ARS Pharmaceuticals make?
ARS Pharmaceuticals reported revenue of $84.28M for fiscal 2025, down 5.46% from fiscal 2024.
Does ARS Pharmaceuticals pay a dividend?
ARS Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from ARS Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures